Clinical Trials Using Montanide ISA 51 VG
Clinical trials are research studies that involve people. The clinical trials on this list are studying Montanide ISA 51 VG. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Montanide and / or Poly-ICLC with Oxidized Tumor Cell Lysate Vaccine and Sargramostim in Treating Patients with Advanced Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This randomized pilot early phase I trial studies montanide (montanide ISA 51 VG) and / or poly-ICLC with oxidized tumor cell lysate vaccine and sargramostim in treating patients with stage III-IV ovarian, primary peritoneal, or fallopian tube cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Biological therapies, such as montanide ISA 51 VG and poly-ICLC, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as sargramostim, may increase the production of blood cells. Giving montanide ISA 51 VG and / or poly-ICLC together with oxidized tumor cell lysate vaccine and sargramostim may be a better treatment for ovarian, primary peritoneal, or fallopian tube cancer.
Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania